What does Tarsus Pharmaceuticals, Inc. do?

Jun 22 2025 07:01 PM IST
share
Share Via
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic conditions. As of March 2025, it reported net sales of $78 million and a net loss of $25 million, with a market cap of $1.66 billion.
Overview:
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic candidates for ophthalmic conditions within the Pharmaceuticals & Biotechnology industry. Financial Snapshot: Most recent Net Sales: 78 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) Market cap: USD 1,656.20 Million (Micro Cap) Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.98 Return on Equity: -30.08% Price to Book: 4.84 Contact Details: Address: 15440 Laguna Canyon Road, IRVINE CA: 92618 Tel: 1 949 4099820 Website: https://www.tarsusrx.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News